Integra LifeSciences (IART) Reports In-Line Q4 EPS, Offers FY Guidance

Integra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.52, in-line with the analyst estimate of $0.52. Revenue for the quarter came in at $255.7 million versus the consensus estimate of $257.27 million.

GUIDANCE:

Integra LifeSciences sees FY2017 EPS of $1.88-$1.94, versus the consensus of $1.93. Integra LifeSciences sees FY2017 revenue of $1.12-1.14 billion, versus the consensus of $1.11 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Piper Sandler defends Oracle ahead of earnings, sees $2.2 billion OCI upside
• Morgan Stanley Comments on Tesla (TSLA) Miam Robotaxi Launch